Q2 2024 |
41 |
$7.51B |
+$255M |
-$1.18B |
-$924M |
UTHR, MDGL, ASND, ARGX, SRPT
|
13F-HR |
8/14/2024, 07:58 AM |
Q1 2024 |
46 |
$8.57B |
+$1.7B |
-$873M |
+$830M |
UTHR, APLS, ASND, SRPT, MDGL
|
13F-HR |
5/15/2024, 08:07 AM |
Q4 2023 |
42 |
$7.24B |
+$1.52B |
-$1.48B |
+$39M |
APLS, UTHR, ASND, ARGX, MDGL
|
13F-HR |
2/14/2024, 12:05 PM |
Q3 2023 |
50 |
$6.4B |
+$267M |
-$764M |
-$497M |
HZNP, UTHR, ARGX, SRPT, APLS
|
13F-HR |
11/14/2023, 06:32 AM |
Q2 2023 |
45 |
$7.37B |
+$486M |
-$166M |
+$320M |
APLS, HZNP, UTHR, SRPT, ARGX
|
13F-HR |
8/14/2023, 08:33 AM |
Q1 2023 |
39 |
$6.74B |
+$304M |
-$21.4M |
+$283M |
HZNP, APLS, UTHR, SRPT, ARGX
|
13F-HR |
5/15/2023, 09:09 AM |
Q4 2022 |
36 |
$6.69B |
+$473M |
-$35.8M |
+$437M |
UTHR, HZNP, APLS, MDGL, ARGX
|
13F-HR |
2/14/2023, 08:04 AM |
Q3 2022 |
39 |
$5.41B |
+$264M |
-$126M |
+$139M |
APLS, UTHR, ARGX, MRTX, SRPT
|
13F-HR |
11/14/2022, 08:28 AM |
Q2 2022 |
39 |
$5.05B |
+$322M |
-$297M |
+$24.6M |
UTHR, ARGX, APLS, HZNP, MRTX
|
13F-HR |
8/15/2022, 08:54 AM |
Q1 2022 |
43 |
$5.48B |
+$789M |
-$296M |
+$492M |
HZNP, UTHR, APLS, MRTX, ARGX
|
13F-HR |
5/16/2022, 08:57 AM |
Q4 2021 |
39 |
$5.86B |
+$640M |
-$253M |
+$388M |
HZNP, MRTX, UTHR, APLS, ARGX
|
13F-HR |
2/14/2022, 08:03 AM |
Q3 2021 |
43 |
$6.36B |
+$625M |
-$364M |
+$262M |
HZNP, MRTX, XLRN, UTHR, ASND
|
13F-HR |
11/15/2021, 09:04 AM |
Q2 2021 |
44 |
$5.74B |
+$644M |
-$498M |
+$147M |
HZNP, MRTX, UTHR, XLRN, ARGX
|
13F-HR |
8/16/2021, 09:05 AM |
Q1 2021 |
46 |
$5.79B |
+$1.09B |
-$373M |
+$721M |
HZNP, MRTX, UTHR, XLRN, VRTX
|
13F-HR |
5/17/2021, 09:29 AM |
Q4 2020 |
44 |
$5.81B |
+$1.14B |
-$304M |
+$834M |
MRTX, HZNP, UTHR, IOVA, ARNA
|
13F-HR |
2/16/2021, 11:33 AM |
Q3 2020 |
45 |
$7.04B |
+$727M |
-$221M |
+$506M |
IMMU, MRTX, HZNP, IOVA, ASND
|
13F-HR |
11/16/2020, 08:02 AM |
Q2 2020 |
44 |
$5.06B |
+$743M |
-$137M |
+$606M |
IMMU, MRTX, HZNP, IOVA, SRPT
|
13F-HR |
8/14/2020, 10:00 AM |
Q1 2020 |
41 |
$2.96B |
+$489M |
-$50.7M |
+$439M |
IMMU, MRTX, IOVA, ASND, BMRN
|
13F-HR |
5/15/2020, 01:03 PM |
Q4 2019 |
30 |
$3.4B |
+$495M |
-$309M |
+$185M |
IMMU, MRTX, ASND, IOVA, SRPT
|
13F-HR |
2/14/2020, 08:47 AM |
Q3 2019 |
33 |
$2.4B |
+$220M |
-$62.6M |
+$158M |
MRTX, IMMU, IOVA, ASND, BMRN
|
13F-HR |
11/14/2019, 11:40 AM |
Q2 2019 |
34 |
$2.89B |
+$531M |
-$40.8M |
+$490M |
MRTX, IMMU, IOVA, ASND, SRPT
|
13F-HR |
8/14/2019, 12:04 PM |
Q1 2019 |
32 |
$2.31B |
+$301M |
-$155M |
+$146M |
IMMU, MRTX, ASND, AMRN, SRPT
|
13F-HR |
5/15/2019, 12:26 PM |
Q4 2018 |
35 |
$1.67B |
+$200M |
-$48.1M |
+$152M |
IMMU, MRTX, SRPT, ASND, BMRN
|
13F-HR |
2/14/2019, 10:11 AM |
Q3 2018 |
45 |
$2.18B |
+$170M |
-$280M |
-$111M |
IMMU, MRTX, SRPT, ASND, BMRN
|
13F-HR |
11/14/2018, 10:16 AM |
Q2 2018 |
41 |
$2.59B |
+$692M |
-$123M |
+$568M |
IMMU, MRTX, BMRN, FOLD, ASND
|
13F-HR |
8/14/2018, 11:25 AM |
Q1 2018 |
52 |
$2.09B |
+$563M |
-$78.5M |
+$484M |
IMMU, FOLD, BMRN, IOVA, MRTX
|
13F-HR |
5/15/2018, 12:51 PM |
Q4 2017 |
44 |
$1.53B |
+$360M |
-$46.2M |
+$314M |
IMMU, BMRN, FOLD, MRTX, CLVSQ
|
13F-HR |
2/14/2018, 10:43 AM |
Q3 2017 |
40 |
$1.27B |
+$446M |
-$93.2M |
+$353M |
IMMU, FOLD, KITE, ARRY, CLVSQ
|
13F-HR |
11/14/2017, 11:23 AM |
Q2 2017 |
43 |
$791M |
+$189M |
-$102M |
+$87.5M |
IMMU, KITE, FOLD, TSRO, BMRN
|
13F-HR |
8/14/2017, 12:30 PM |
Q1 2017 |
42 |
$782M |
+$310M |
-$36.3M |
+$273M |
IMMU, TSRO, MDCO, ACAD, BMRN
|
13F-HR |
5/15/2017, 12:20 PM |
Q4 2016 |
39 |
$494M |
+$101M |
-$36.3M |
+$64.3M |
ACAD, IMMU, BMRN, LBIO, TSRO
|
13F-HR |
2/14/2017, 11:27 AM |
Q3 2016 |
44 |
$563M |
+$109M |
-$39.1M |
+$70M |
SRPT, BMRN, LBIO, TSRO, FOLD
|
13F-HR |
11/14/2016, 02:38 PM |
Q2 2016 |
39 |
$445M |
+$184M |
-$20.2M |
+$164M |
TSRO, LBIO, CPXX, BMRN, BMY
|
13F-HR |
8/15/2016, 04:09 PM |
Q1 2016 |
36 |
$285M |
+$129M |
-$35.6M |
+$93.8M |
MRTX, FOLD, BMRN, SRPT, GILD
|
13F-HR |
5/16/2016, 04:06 PM |
Q4 2015 |
28 |
$290M |
+$23.4M |
-$51.8M |
-$28.5M |
MRTX, FOLD, LBIO, LJPC, SRPT
|
13F-HR |
2/12/2016, 11:00 AM |
Q3 2015 |
32 |
$383M |
+$129M |
-$7.18M |
+$122M |
FOLD, MRTX, VNDA, LJPC, ACAD
|
13F-HR |
11/13/2015, 11:27 AM |
Q2 2015 |
31 |
$363M |
+$142M |
-$10.6M |
+$132M |
FOLD, SRNEQ, MRTX, LBIO, ONTY
|
13F-HR |
8/14/2015, 12:31 PM |
Q1 2015 |
33 |
$243M |
+$120M |
-$20.8M |
+$99.7M |
FOLD, LBIO, SRNEQ, PTX, BLCM
|
13F-HR |
5/15/2015, 11:59 AM |
Q4 2014 |
29 |
$142M |
|
|
|
FOLD, TARO, RCPT, PTX, AGEN
|
13F-HR |
2/13/2015, 12:07 PM |